Search
Pimethixene
go.drugbank.com/drugs/DB13292ApprovedPimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. It is an anticholinergic used in the treatment of bronchitis.
Glisoxepide
go.drugbank.com/drugs/DB01289InvestigationalHowever it inhibits taurocholate uptake only in the absence of sodium ions.
Categories: Drugs Used in DiabetesPolistes fuscatus venom protein
go.drugbank.com/drugs/DB10959ApprovedPolistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.
Polistes metricus venom protein
go.drugbank.com/drugs/DB11029ApprovedPolistes metricus venom protein is an extract of Polistes metricus venom. Polistes metricus venom protein is used in allergenic testing.
Vespula squamosa venom protein
go.drugbank.com/drugs/DB11032ApprovedVespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Diacetyl benzoyl lathyrol
go.drugbank.com/drugs/DB11260ApprovedDiacetyl benzoyl lathyrol is an active ingredient in whitening creams. It is also reported to be a skin conditioning agent.
Eleuthero
go.drugbank.com/drugs/DB14303ApprovedInvestigationalEleuthero is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: Ci Wu Jia, Et Maxim.) Maxim. RootGS030-DP
go.drugbank.com/drugs/DB17847InvestigationalGS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. … It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Azetukalner
go.drugbank.com/drugs/DB21551InvestigationalAzetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da. … The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel.
Reviparin
go.drugbank.com/drugs/DB09259Approved[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]